rxstat › Shortages › Adalimumab

Adalimumab shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Adalimumab products are in shortage in Canada (1 of 7 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
Products affected
1 of 7
Reports on file
11
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.

Reports by product

Active shortage
ABRILADA
20MG · SOLUTION · PFIZER CANADA ULC
DIN 02511061 · since ?, no end estimate · Disruption of the manufacture of the drug.
To be discontinued
HUMIRA
40MG · SOLUTION · ABBVIE CORPORATION
DIN 02258595
Resolved
ABRILADA
40MG · SOLUTION · PFIZER CANADA ULC
DIN 02511045 · ended Nov 14, 2025 · Disruption of the manufacture of the drug.
Resolved
HULIO
40MG · SOLUTION · BGP PHARMA ULC
DIN 02502402 · ended Feb 1, 2023 · Disruption of the manufacture of the drug.
Resolved
HULIO
40MG · SOLUTION · BGP PHARMA ULC
DIN 02502399 · ended Jan 19, 2023 · Disruption of the manufacture of the drug.
Avoided
ABRILADA
40MG · SOLUTION · PFIZER CANADA ULC
DIN 02511053 · ended Dec 7, 2022 · Disruption of the manufacture of the drug.
Resolved
HULIO
20MG · SOLUTION · BGP PHARMA ULC
DIN 02502380 · ended Dec 7, 2022 · Disruption of the manufacture of the drug.
Resolved
HULIO
40MG · SOLUTION · BGP PHARMA ULC
DIN 02502402 · ended Nov 21, 2022 · Disruption of the manufacture of the drug.
Resolved
HULIO
40MG · SOLUTION · BGP PHARMA ULC
DIN 02502399 · ended Nov 9, 2022 · Disruption of the manufacture of the drug.
Resolved
HULIO
40MG · SOLUTION · BGP PHARMA ULC
DIN 02502402 · ended Oct 21, 2022 · Disruption of the manufacture of the drug.
Discontinued
HUMIRA VIAL
40MG · SOLUTION · ABBVIE CORPORATION
DIN 02258595

What's happening

Adalimumab is currently affected by an active shortage report filed with Health Canada by PFIZER CANADA ULC.

The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Adalimumab is classified under “IMMUNOSUPPRESSANTS” (ATC L04AB).

Recent changes

Common questions

When will Adalimumab be back in stock in Canada?

Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.

Why is Adalimumab in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Related drugs (immunosuppressants)

Widespread shortageApremilast2 of 3 reported products affectedPartial shortageApremilast Apremilast Apremilast1 of 1 reported products affected · est. return Aug 28, 2026Partial shortageBasiliximab1 of 1 reported products affectedPartial shortageCyclosporine1 of 8 reported products affected · est. return Jul 30, 2027Partial shortageFingolimod3 of 8 reported products affectedPartial shortageLeflunomide3 of 15 reported products affected · est. return Jul 24, 2026

All immunosuppressants shortage statuses →

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.